olmesartan medoxomil has been researched along with Blood Pressure, High in 226 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.44) | 18.2507 |
| 2000's | 115 (50.88) | 29.6817 |
| 2010's | 99 (43.81) | 24.3611 |
| 2020's | 11 (4.87) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, W; Guo, X; Jiang, H; Jin, X; Liu, Y; Sun, P; Yu, J | 1 |
| Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y | 1 |
| Burnier, M; Redon, J; Volpe, M | 1 |
| Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J | 1 |
| Burnier, M; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 1 |
| Gabb, GM; Moore, K; Shukla, N | 1 |
| Chockalingam, KC; Jayagopal, PB; Khan, MY; Mane, A; Mehta, S; Oomman, A; Pandit, S; Ramakrishnan, A; Shah, S | 1 |
| Adachi, O; Akiyama, M; Kumagai, K; Motoyoshi, N; Saiki, Y; Sasaki, K; Sato, M; Sugawara, Y | 1 |
| Feng, YQ; Kario, K; Ma, CS; Wang, JG; Wang, TD; Zhang, M; Zhu, ZM | 1 |
| Battistoni, A; Citoni, B; Figliuzzi, I; Gallo, G; Presta, V; Tocci, G; Volpe, M | 1 |
| Dushkin, AV; Feng, Z; Ren, W; Su, W; Zhang, Q; Zhao, Y | 1 |
| Battistoni, A; Coluccia, R; Mastromarino, V; Santolamazza, C; Tocci, G; Volpe, M | 2 |
| Costa, FV | 1 |
| Srinivas, NR | 1 |
| Thomopoulos, C | 1 |
| Jani, P; Pandya, NT; Tandel, H; Vanza, J | 1 |
| Redon, J; Reimitz, PE; Wang, JG; Weber, MA | 1 |
| van der Merwe, WM | 1 |
| Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L | 1 |
| Chin, HJ; Choi, BS; Kim, DK; Lee, SH; Lim, CS; Park, JH; Shin, SJ; Yu, MY | 1 |
| Ferri, C; Ferri, L | 1 |
| Malacco, E; Mallion, JM; Omboni, S; Volpe, M | 2 |
| Ahmad, S; Batlle, D; Brosnihan, KB; Ferrario, CM; Moniwa, N; Varagic, J; VonCannon, JL; Wysocki, J | 1 |
| Fernandez, V; Heyrman, R; Izzo, JL; Lee, J; Lewin, AJ; Melino, M | 1 |
| Maa, JF; Nesbitt, S; Shojaee, A | 1 |
| Estato, V; Gomes, MB; Kaiser, SE; Sanjuliani, AF; Tibiriçá, E | 1 |
| Maa, JF; Shojaee, A; Weir, MR | 1 |
| Fernandez, V; Heyrman, R; Lee, J; Melino, M; Oparil, S; Roth, EM | 1 |
| Furusu, A; Kohno, S; Koji, T; Miyazaki, T; Nishino, T; Obata, Y; Sato, Y; Uramatsu, T | 1 |
| Asai, S; Kanou, N; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y | 1 |
| Aranda-Lara, P; Frutos-Sanz, MA; Goyache-Goñi, B; Hernández-Marrero, D; Reyes-Engels, A | 1 |
| Boscaro, E; Calò, LA; Dal Maso, L; Facco, M; Maiolino, G; Pagnin, E; Pessina, AC; Ravarotto, V; Rossi, GP | 1 |
| Choudhury, H; Gorain, B; Jaisankar, P; Karmakar, S; Kundu, A; Pal, TK; Sarkar, L | 1 |
| Punzi, HA | 2 |
| Chrysant, SG; Fernandez, V; Izzo, JL; Kereiakes, DJ; Lee, J; Lewin, AJ; Melino, M; Oparil, S | 1 |
| Kaul, U; Mansoor, A; Sabbah, ZA | 1 |
| Janssen, J; Mulder, CJ; Nijeboer, P; van Beurden, YH; Verbeek, WH | 1 |
| Gao, PJ; Zhang, SY; Zhu, JR | 1 |
| Baser, O; Frech-Tamas, F; Marrett, E; Xie, L | 1 |
| Jiang, H; Ke, Y; Li, J; Qin, T; Wang, H | 1 |
| Hair, C; Heerasing, N; Wallace, S | 1 |
| Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M | 1 |
| Hirasawa, M; Kageji, T; Kanematsu, Y; Kitazato, KT; Kuwayama, K; Matsushita, N; Matsuura, E; Nagahiro, S; Nishi, K; Satomi, J; Shimada, K; Tada, Y; Uno, M; Yagi, K | 1 |
| An, JN; Chin, HJ; Choi, BS; Hwang, JH; Kim, DK; Kim, S; Lee, JP; Lee, SH; Lim, CS; Park, JH; Shin, SJ | 1 |
| Ammentorp, B; Laeis, P; Rump, LC; Scholze, J | 1 |
| Calò, LA; Carraro, G; Fragasso, A; Maiolino, G; Pagnin, E; Ravarotto, V; Rossi, B | 1 |
| Asai, S; Nakayama, T; Nishida, Y; Susa, N; Takahashi, Y; Yada, Y | 1 |
| Chung, WB; Hong, TJ; Kim, BS; Kim, CJ; Oh, BH; Park, CG; Sohn, IS | 1 |
| Cao, C; Perez, A | 1 |
| Kodati, D; Kotakonda, HK; Yellu, N | 1 |
| Ahn, Y; Baek, SH; Choi, DH; Hong, TJ; Hyon, MS; Jeong, JO; Kang, WC; Kim, HS; Kim, SH; Kim, YH; Lee, SC; Nam, CW; Park, JS; Park, TH; Seo, HS; Shim, WJ; Shin, JH | 1 |
| McCormack, PL; Scott, LJ | 1 |
| Kasal, DA; Mandarim-de-Lacerda, CA; Neves, MF; Oigman, W | 1 |
| Amodeo, C; Brandão, AA; Feitosa, AD; Gomes, MA; Moriguchi, EH; Oigman, W; Précoma, DB; Ribeiro, AB; Ribeiro, JM; Saraiva, JF | 1 |
| Brommer, P; Haag, U; Miele, C; Volpe, M | 1 |
| Heagerty, AM; Mallion, JM | 1 |
| Hiramatsu, K; Ishikawa, M; Komiya, M; Kushiro, T; Matsushita, Y; Sagawa, K; Saito, I | 1 |
| Chavanu, KJ; Chrysant, SG; Dubiel, R; Kereiakes, D; Oparil, S; Waverczak, W; Xu, J | 1 |
| Ram, CV | 2 |
| Furukawa, T; Hatsuno, T; Isshiki, T; Nagaoka, K; Sagawa, T; Ueno, Y; Watari, Y; Yamakawa, T | 1 |
| Hiramatsu, K; Hirata, K; Kobayashi, F; Komiya, M; Kushiro, T; Sagawa, K; Saito, I; Sato, Y | 2 |
| Hiramatsu, K; Hirata, K; Ishikawa, M; Komiya, M; Kushiro, T; Matsushita, Y; Sagawa, K; Saito, I; Yamashita, T | 1 |
| Neutel, JM | 2 |
| Keam, SJ; Sanford, M | 1 |
| Haag, U; Miele, C; Volpe, M | 1 |
| Barrios, V; Brommer, P; Calderón, A; Escobar, C; Haag, U | 1 |
| Albayrak, S; Alemdar, R; Aydin, M; Kaya, A; Ordu, S; Ozhan, H; Yazici, M | 1 |
| Rosenson, RS | 1 |
| Chavanu, KJ; Chrysant, SG; Xu, J | 1 |
| Chrysant, SG | 4 |
| Cagnoni, F; Christian Achiri, NN; D'Ospina, A; Destro, M; Preti, P; Ricci, AR | 1 |
| Dubiel, R; Kereiakes, DJ; Neutel, J; Shojaee, A; Stoakes, KA; Waverczak, WF; Xu, J | 1 |
| Karki, S; Lee, J; Melino, M; Oparil, S | 1 |
| Arakawa, K; Kuramoto, K; Tanigawara, Y; Yoshihara, K | 1 |
| Barrios, V; Böhm, M; Calderon, A; Escobar, C | 1 |
| Kuramoto, K; Ogihara, T; Saruta, T; Shimada, K | 2 |
| Hiramatsu, K; Kushiro, T; Matsushita, Y; Saito, I; Sugihara, M | 1 |
| Krzesinski, JM; Scheen, AJ | 2 |
| Oparil, S; Pimenta, E | 1 |
| Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M; Oparil, S | 1 |
| Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J | 1 |
| Bhorat, AE; Hazan, L; Hernández Rodriguez, OA; Heyrman, R; Miyazaki, K; Tao, B | 1 |
| Baszak, J; Fogari, R; Holm-Bentzen, M; Melani, L; Schumacher, K; Taddei, S | 1 |
| Rana, R; Singh, A | 1 |
| Dubiel, R; Kereiakes, DJ; Maa, JF; Shojaee, A | 1 |
| Fernandez, V; Heyrman, R; Lee, J; Melino, M; Oparil, S | 1 |
| Böhm, M; Schmieder, RE | 1 |
| Rump, LC; Sellin, L | 1 |
| Kereiakes, DJ; Neutel, JM | 2 |
| Kereiakes, DJ; Neutel, J | 1 |
| Auteri, A; Malacco, E; Omboni, S; Volpe, M; Zanchetti, A | 1 |
| Wilford Germino, F | 1 |
| Barton, J; Mallion, JM; Narkiewicz, K; Omboni, S; Panzer, PK; Puig, JG; Stefanadis, C; Van Mieghem, W; Zweiker, R | 1 |
| Girerd, X; Rump, LC; Sellin, L; Stegbauer, J | 1 |
| Keating, GM; Muir, VJ | 1 |
| Hirata, T; Horimai, C; Irie, J; Itoh, H; Kawai, T; Matsumoto, H; Saisho, Y; Shimada, A; Takei, I; Tanaka, K | 1 |
| Chavanu, KJ; Dubiel, R; Flack, JM; Li, W; Punzi, HA; Stoakes, KA; Weir, MR | 1 |
| Tocci, G; Volpe, M | 2 |
| Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA | 1 |
| Caielli, P; Cal, LA; Davis, PA; Fusaro, M; Maso, LD; Pagnin, E; Pessina, AC | 1 |
| Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A | 1 |
| Axt-Fliedner, R; Enzensberger, C; Eskef, K; Faas, D; Schwarze, A | 1 |
| Mason, RP | 1 |
| Igata, H; Imanishi, M; Kawaguchi, N; Kuroita, T; Kusumoto, K; Nagaya, H; Nishigaki, N; Ojima, M; Sakamoto, H; Tsuboi, A; Yamaguchi, F | 1 |
| Khan, BV | 1 |
| Akizawa, T; Honda, H; Niikura, K; Suzuki, R | 1 |
| Ferrario, CM; Igase, M; Yokoyama, H | 1 |
| Girerd, X; Rosenbaum, D | 1 |
| Carrothers, TJ; Heyrman, R; Rohatagi, S; Salazar, DE; Shi, J; Song, SH; Wada, DR | 1 |
| Baulmann, J; Becker, ST; Dahlöf, B; Kaschina, E; Lucht, K; Paulis, L; Schwengel, K; Slavic, S; Steckelings, UM; Thöne-Reineke, C; Unger, T | 1 |
| Erdine, S | 1 |
| Hirooka, Y; Kishi, T; Ogawa, K; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K | 1 |
| Barrios, V; de la Sierra, A | 1 |
| Chavanu, KJ; Flack, JM; Graff, A; Li, W | 1 |
| Hiramatsu, K; Kawamori, R; Kobayashi, F; Miyazaki, S; Shirayama, M; Teramoto, T; Teramukai, S | 1 |
| Chavanu, KJ; Lewin, A; Li, W; Punzi, HA | 1 |
| Maa, JF; Punzi, H; Shojaee, A | 1 |
| Blowey, DL; Blumer, J; Heyrman, R; Rohatagi, S; Salazar, DE; Sherbotie, JR; Song, S; Sullivan, JE; Wells, TG | 1 |
| Liu, B; Shi, D; Shi, XY; Wang, L; Zhao, JW; Zou, Z | 1 |
| Chavanu, KJ; Dubiel, R; Germino, FW; Maa, JF; Neutel, JM | 1 |
| Hou, MW; Jiang, H; Ke, YN; Sun, NL; Wang, JG; Zhu, JR | 1 |
| Ikegami, N; Ke, YN; Sun, NL; Wang, JG; Zhang, BH; Zhu, JR | 1 |
| Hsueh, WA; Maa, JF; Neutel, JM; Shojaee, A | 1 |
| Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn, T; Melino, M | 1 |
| Chrysant, SG; Germino, FW; Neutel, JM | 1 |
| Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR | 1 |
| Cervenka, L; Fukuoka, N; Hitomi, H; Houchi, H; Kobara, H; Kobori, H; Kosaka, S; Masaki, T; Matsumura, Y; Mori, H; Nakano, D; Nishiyama, A; Pelisch, N; Rahman, M | 1 |
| Adachi, Y; Fukamizu, A; Garbers, DL; Harada, M; Izumi, T; Kawakami, R; Kishimoto, I; Kuwahara, K; Li, Y; Nakagawa, Y; Nakanishi, M; Nakao, K; Saito, Y; Takahashi, N; Tanimoto, K | 1 |
| Berardinelli, C; Kupecz, D | 1 |
| Smith, DH | 1 |
| Franks, AM; Gardner, SF | 1 |
| Hobara, N; Inaizumi, K; Kawasaki, H; Kurosaki, Y; Nakamura, A | 1 |
| Chrysant, SG; Marbury, TC; Robinson, TD | 1 |
| Fujita, T; Inagi, R; Kurokawa, K; Miyata, T; Nangaku, M; Shao, J; Yamada, K | 1 |
| Brousil, JA; Burke, JM | 1 |
| Terra, SG | 1 |
| Averill, DB; Brosnihan, KB; Chappell, MC; Ferrario, CM; Gallagher, PE | 1 |
| Brunner, HR; Laeis, P | 1 |
| Dominiak, P; Häuser, W | 1 |
| Ishii, M | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Nishio, M; Ohtani, T; Sakata, Y; Yamamoto, K; Yoshida, J | 1 |
| Chrysant, GS; Chrysant, SG | 1 |
| Kobori, H; Navar, LG; Ozawa, Y; Prieto-Carrasquero, MC | 1 |
| Charo, IF; Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Ishibashi, T; Kitamoto, S; Kura, S; Ohtani, K; Sugaya, T; Takeshita, A; Tsuchihashi, M; Tsuzuki, T; Zhao, Q | 1 |
| Masonson, HN; Neutel, JM; Smith, DH; Wang, AC; Weber, MA | 1 |
| Arakawa, K | 1 |
| Brunner, HR | 3 |
| Wehling, M | 1 |
| Stumpe, KO | 1 |
| Abe, Y; Fan, Y; Kimura, S; Kobori, H; Nishiyama, A; Rahman, M; Seth, DM; Shokoji, T; Yao, L; Zhang, GX | 1 |
| Buchholz, K; Fliser, D; Haller, H | 1 |
| Giles, TD; Robinson, TD | 1 |
| Furuhashi, M; Higashiura, K; Moniwa, N; Murakami, H; Shimamoto, K; Takizawa, H; Ura, N; Yoshida, D | 1 |
| Mizuno, M; Sada, T | 1 |
| Böhm, M; McInnes, GT; Neutel, JM; Unger, T | 1 |
| Ewald, S; Kaufmann, S; Mengden, T; Uen, S; Vetter, H; vor dem Esche, J | 1 |
| Dubiel, R; Jones, M; Smith, DH | 1 |
| Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Yoshida, K; Yoshiyama, M | 1 |
| Ferrario, CM; Gallagher, PE; Geary, RL; Igase, M; Strawn, WB | 1 |
| Arakawa, N; Fujimori, I; Inoue, T; Nakamura, H; Shimakawa, E; Shimizu, Y; Toyoshi, T; Yokoyama, T; Yoshigae, Y | 1 |
| Agabiti-Rosei, E; Bianchi, R; Boari, GE; Castellano, M; De Ciuceis, C; Paiardi, S; Porteri, E; Rezzani, R; Rizzoni, D; Rodella, L; Sleiman, I | 1 |
| Mire, DE; Pugsley, MK; Silfani, TN | 1 |
| Brunner, HR; Burnier, M; Forclaz, A; Hasler, C; Maillard, M; Nussberger, J | 1 |
| Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K | 1 |
| Lee, Y; Neutel, JM; Silfani, TN; Smith, DH; Weber, MA | 1 |
| Ambrosioni, E; Burnier, M; Hörl, W; Rabelink, AJ; Rump, LC | 1 |
| Chavanu, K; Merkel, J; Quan, A | 1 |
| Chrysant, SG; Marbury, TC; Silfani, TN | 1 |
| Bolbrinker, J; Huber, M; Kreutz, R | 1 |
| Averill, DB; Brosnihan, KB; Cooke, L; Ferrario, CM; Schiffrin, EL; Smith, RD; Yokoyama, H | 1 |
| Arakawa, K; Brunner, HR | 1 |
| Ewald, S; Mengden, T; Neikes, F; Uen, S; Vetter, H; vor dem Esche, J | 1 |
| Dubiel, R; Izzo, JL; Neutel, JM; Silfani, T; Walker, F | 1 |
| Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR | 1 |
| Greathouse, M | 1 |
| Nykamp, D; Winter, EE | 1 |
| Giles, TD; Oparil, S; Silfani, TN; Walker, JF; Wang, A | 1 |
| Fay, R; Zannad, F | 1 |
| Lancellotti, P | 1 |
| Fernández-Torres, C; Jaén Aguila, F; Jiménez-Alonso, J; Mediavilla García, JD | 1 |
| Barrios, V; Boccanelli, A; Böhm, M; Ewald, S; Girerd, X; Heagerty, A; Krzesinski, JM; Lins, R; Rodicio, J; Stefenelli, T; Woittiez, A | 1 |
| Heagerty, A; Laeis, P; Mallion, JM | 1 |
| Dubiel, R; Kereiakes, DJ; Lipka, LJ; Neutel, JM; Punzi, HA; Xu, J | 1 |
| Barrios, V; Escobar, C | 1 |
| Gong, HP; Li, L; Ma, ZY; Song, T; Tan, HW; Wang, ZH; Zhang, W; Zhang, Y; Zhong, M; Zhong, XZ | 1 |
| Carrothers, TJ; Khariton, T; Kshirsagar, S; Lee, J; Rohatagi, S; Salazar, D | 1 |
| Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M | 1 |
| Brunner, HR; Laeis, P; Nussberger, J; Püchler, K; Witte, PU | 1 |
| Higashiura, K; Li, Y; Shimamoto, K; Takada, M; Takada, T; Takizawa, H; Togashi, N; Torii, T; Ura, N | 1 |
| Higashiura, K; Murakami, H; Shimamoto, K; Togashi, N; Ura, N | 1 |
| Danser, AH; Schuijt, MP | 1 |
| Weber, MA | 1 |
| Brunner, HR; Nussberger, J | 1 |
| Gonzalez, L; Laeis, P; Püchler, K; Schwocho, LR; Sudhop, T; von Bergmann, K | 1 |
| Ball, KJ; Stumpe, KO; Williams, PA | 1 |
| Kohzuki, M; Wu, XM; Xu, HL; Yoshida, K | 1 |
| Ichikawa, S; Takayama, Y | 1 |
| Oparil, S | 1 |
52 review(s) available for olmesartan medoxomil and Blood Pressure, High
| Article | Year |
|---|---|
Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Leukemia, Myeloid, Acute; Olmesartan Medoxomil | 2023 |
Is the newest angiotensin-receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta-analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensins; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension; Network Meta-Analysis; Olmesartan Medoxomil; Oxadiazoles; Tetrazoles | 2021 |
ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Comorbidity; COVID-19; Humans; Hypertension; Olmesartan Medoxomil; Pandemics; Pneumonia, Viral; Renin-Angiotensin System; SARS-CoV-2 | 2021 |
Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Precision Medicine; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Substitution; Drug Therapy, Combination; Drugs, Generic; Humans; Hypertension; Imidazoles; Medication Adherence; Olmesartan Medoxomil; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients.
Topics: Aged; Angiotensin Receptor Antagonists; Blood Pressure; Humans; Hypertension; Middle Aged; Olmesartan Medoxomil; Treatment Outcome | 2018 |
Olmesartan medoxomil: a review of its use in the management of hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2008 |
Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Placebos; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2009 |
Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Practice Guidelines as Topic; Tetrazoles | 2009 |
Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug Combinations; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2009 |
Olmesartan medoxomil/amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome | 2009 |
Olmesartan medoxomil: recent clinical and experimental acquisitions.
Topics: Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2009 |
Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Sodium Chloride Symporter Inhibitors; Tetrazoles; Treatment Outcome | 2010 |
Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement.
Topics: Angiotensin Receptor Antagonists; Blood Pressure Determination; Cardiovascular Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2010 |
Olmesartan medoxomil: in children and adolescents with hypertension.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Child; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2010 |
Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2011 |
Olmesartan medoxomil for the treatment of hypertension in children and adolescents.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Child; Evidence-Based Medicine; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Risk Assessment; Tetrazoles; Treatment Outcome | 2011 |
Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Breech Presentation; Cesarean Section; Drug Substitution; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Infant; Infant, Newborn; Kidney; Oligohydramnios; Olmesartan Medoxomil; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, First; Tetrazoles; Ultrasonography, Prenatal | 2012 |
Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Humans; Hypertension; Imidazoles; Inflammation Mediators; Nitric Oxide; Olmesartan Medoxomil; Renin-Angiotensin System; Tetrazoles; Treatment Outcome | 2011 |
Fixed-combination therapy to improve blood pressure control: experience with olmesartan-based therapy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Risk Factors; Tetrazoles | 2011 |
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Losartan; Olmesartan Medoxomil; Reproducibility of Results; Tetrazoles | 2011 |
Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Design; Fumarates; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Medication Adherence; Olmesartan Medoxomil; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tetrazoles; Valine; Valsartan | 2011 |
Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Combinations; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Practice Guidelines as Topic; Tetrazoles | 2012 |
Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome | 2012 |
Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Risk; Tetrazoles | 2012 |
Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2002 |
Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Prescription Fees; Receptors, Angiotensin; Tetrazoles | 2003 |
Olmesartan medoxomil: an angiotensin II-receptor blocker.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Drug Interactions; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2003 |
Clinical efficacy of olmesartan medoxomil.
Topics: Antihypertensive Agents; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2003 |
[Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles | 2004 |
Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors; Tetrazoles | 2004 |
[Development of combined drugs (ARB and diuretics)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Diuretics; Drug Combinations; Drug Design; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Kidney Tubules, Proximal; Losartan; Olmesartan Medoxomil; Practice Guidelines as Topic; Renin-Angiotensin System; Sodium; Telmisartan; Tetrazoles | 2004 |
Clinical efficacy and tolerability of olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Meta-Analysis as Topic; Olmesartan Medoxomil; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome | 2004 |
Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relationship, Drug; Food-Drug Interactions; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Patient Compliance; Receptor, Angiotensin, Type 1; Tetrazoles | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
The role of olmesartan medoxomil in the management of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2004 |
Telemonitoring of blood pressure self measurement in the OLMETEL study.
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Self Care; Telemedicine; Tetrazoles | 2004 |
A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Humans; Hypertension; Imidazoles; Molecular Structure; Olmesartan Medoxomil; Protein Binding; Structure-Activity Relationship; Tetrazoles | 2005 |
Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Creatinine; Europe; Female; Healthy Volunteers; Humans; Hypertension; Imidazoles; Japan; Linear Models; Male; Middle Aged; Models, Biological; Olmesartan Medoxomil; Prodrugs; Retrospective Studies; Tetrazoles; United States | 2005 |
A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; Factor Analysis, Statistical; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2006 |
Olmesartan medoxomil: current status of its use in monotherapy.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analysis; Drug Costs; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Research Design; Tetrazoles; Treatment Outcome | 2006 |
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Administration Schedule; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2006 |
Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Imidazoles; Middle Aged; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2007 |
[Medication of the month. Olmesartan medoxomil hydroclorothiazide (Olmetec Plus or Belsar Plus].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2007 |
Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2008 |
Clinical studies of CS-866, the newest angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2001 |
The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2002 |
Comparative antihypertensive efficacy of olmesartan: comparison with other angiotensin II receptor antagonists.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diuretics; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2002 |
86 trial(s) available for olmesartan medoxomil and Blood Pressure, High
| Article | Year |
|---|---|
Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Prospective Studies; Randomized Controlled Trials as Topic; Tetrazoles; Thioctic Acid | 2022 |
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.
Topics: Aged; Benzimidazoles; Chlorthalidone; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Oxadiazoles; Renal Insufficiency, Chronic; Treatment Outcome | 2018 |
Albuminuria during treatment with angiotensin type II receptor blocker is a predictor for GFR decline among non-diabetic hypertensive CKD patients.
Topics: Aged; Albuminuria; Angiotensin II Type 2 Receptor Blockers; Area Under Curve; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Olmesartan Medoxomil; Renal Insufficiency, Chronic; Risk Factors; ROC Curve | 2018 |
Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.
Topics: Adolescent; Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2013 |
Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Substitution; Ethnicity; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2013 |
Antihypertensive treatment improves microvascular rarefaction and reactivity in low-risk hypertensive individuals.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Capillaries; Female; Humans; Hypertension; Imidazoles; Male; Metoprolol; Microcirculation; Middle Aged; Olmesartan Medoxomil; Skin; Tetrazoles | 2013 |
Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Treatment Outcome; Young Adult | 2013 |
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Obesity; Olmesartan Medoxomil; Prevalence; Tetrazoles; Treatment Outcome | 2013 |
Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Treatment Outcome | 2014 |
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Hispanic or Latino; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Least-Squares Analysis; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2014 |
Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; China; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Young Adult | 2014 |
[The effects of olmesartan on ambulatory blood pressures and blood pressure variability in patients with mild to moderate essential hypertension].
Topics: Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Essential Hypertension; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2014 |
Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Quality of Life; Tetrazoles; Treatment Outcome | 2015 |
Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
Topics: Aged; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; beta 2-Glycoprotein I; Biomarkers; Blood Pressure; Drug Substitution; Female; Humans; Hypertension; Japan; Lipoproteins, LDL; Male; Middle Aged; Olmesartan Medoxomil; Peptide Fragments; Peroxiredoxins; Prospective Studies; Stroke; Time Factors; Treatment Outcome | 2015 |
The Decrement of Hemoglobin Concentration with Angiotensin II Receptor Blocker Treatment Is Correlated with the Reduction of Albuminuria in Non-Diabetic Hypertensive Patients: Post-Hoc Analysis of ESPECIAL Trial.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Case-Control Studies; Erythropoietin; Female; Hemoglobins; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Receptors, Angiotensin; Renin-Angiotensin System; Treatment Outcome | 2015 |
Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual-Combination Therapy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Diuretics; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Olmesartan Medoxomil | 2016 |
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Young Adult | 2016 |
Azilsartan in Patients With Mild to Moderate Hypertension Using Clinic and Ambulatory Blood Pressure Measurements.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Double Bind Interaction; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Oxadiazoles; Treatment Outcome | 2017 |
Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT:
Topics: Antihypertensive Agents; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Republic of Korea; Rosuvastatin Calcium | 2016 |
Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2009 |
Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2008 |
Blood pressure-lowering effects of angiotensin receptor antagonist monotherapy and in combination with other anti-hypertensive drugs in primary care settings in Japan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Japan; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Treatment Outcome | 2009 |
Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Diuretics; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Practice Guidelines as Topic; Tetrazoles | 2009 |
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2009 |
Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.
Topics: Angiotensin II Type 1 Receptor Blockers; Cystatin C; Diastole; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Kidney; Kidney Function Tests; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2009 |
Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cell Adhesion Molecules; Cytokines; Double-Blind Method; Fatty Acids, Nonesterified; Female; Humans; Hypertension; Imidazoles; Lipopolysaccharides; Male; Metabolic Syndrome; Middle Aged; Olmesartan Medoxomil; Oxidation-Reduction; Oxidative Stress; Tetrazoles | 2009 |
Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2009 |
The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Single-Blind Method; Tetrazoles; Treatment Outcome | 2009 |
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Patient Positioning; Prospective Studies; Severity of Illness Index; Tetrazoles; Treatment Outcome; United States | 2009 |
Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Clinical Laboratory Techniques; Cross-Over Studies; Dihydropyridines; Female; Humans; Hypertension; Imidazoles; Individuation; Male; Middle Aged; Olmesartan Medoxomil; Population Groups; Tetrazoles | 2009 |
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Practice Guidelines as Topic; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome | 2009 |
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Asian People; Azetidinecarboxylic Acid; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2009 |
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Middle Aged; Olmesartan Medoxomil; Placebo Effect; Racial Groups; Tetrazoles; Time Factors; Treatment Outcome; United States | 2010 |
A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.
Topics: Administration, Oral; Adolescent; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Child; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Linear Models; Male; Maximum Tolerated Dose; Olmesartan Medoxomil; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2010 |
Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dizziness; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2010 |
Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, mult
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Diuretics; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome | 2010 |
Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Female; Humans; Hypertension; Imidazoles; India; Male; Middle Aged; Olmesartan Medoxomil; Product Surveillance, Postmarketing; Tetrazoles; Treatment Outcome; Young Adult | 2010 |
Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
Topics: Aged; Algorithms; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2010 |
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles | 2010 |
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Therapy, Combination; Female; Heart Rate; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2010 |
Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Sex Factors; Tetrazoles; Treatment Outcome | 2011 |
An olmesartan medoxomil-based treatment algorithm is effective in achieving 24-hour BP control in patients with type 2 diabetes mellitus, regardless of age, race, sex, or severity of hypertension: subgroup analysis of the BENIFICIARY study.
Topics: Adult; Age Factors; Aged; Algorithms; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Sex Characteristics; Tetrazoles | 2010 |
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring.
Topics: Aged; Algorithms; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Placebos; Prospective Studies; Tetrazoles | 2010 |
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Placebos; Ramipril; Systole; Tetrazoles; Time Factors; Treatment Outcome | 2010 |
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Diastole; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Ramipril; Systole; Tetrazoles | 2011 |
Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2011 |
Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2011 |
A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2011 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2011 |
Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Euphoria; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Young Adult | 2011 |
Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Female; Humans; Hypertension; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Prospective Studies; Renal Dialysis; Renin; Tetrazoles | 2012 |
Olmesartan medoxomil combined with hydrochlorothiazide improves 24-hour blood pressure control in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2012 |
Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension.
Topics: Analysis of Variance; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Least-Squares Analysis; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Placebos; Prospective Studies; Tetrazoles; Treatment Outcome | 2012 |
Efficacy/safety of olmesartan medoxomil versus losartan potassium in naïve versus previously treated subjects with hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Ethnicity; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2012 |
Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.
Topics: Adolescent; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Child; Child, Preschool; Female; Half-Life; Humans; Hypertension; Imidazoles; Infant; Male; Olmesartan Medoxomil; Tetrazoles | 2012 |
Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Treatment Outcome | 2012 |
Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; China; Humans; Hypertension; Imidazoles; Intention to Treat Analysis; Middle Aged; Office Visits; Olmesartan Medoxomil; Predictive Value of Tests; Prospective Studies; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Obesity; Olmesartan Medoxomil; Tetrazoles | 2012 |
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Renal Insufficiency, Chronic; Tetrazoles | 2012 |
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Imidazoles; Male; Metabolic Syndrome; Monitoring, Physiologic; Olmesartan Medoxomil; Ramipril; Safety; Tetrazoles | 2012 |
Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors; Treatment Outcome | 2013 |
Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome | 2003 |
Use of an olmesartan medoxomil-based treatment algorithm for hypertension control.
Topics: Algorithms; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2004 |
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; C-Reactive Protein; Chemokine CCL2; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Olmesartan Medoxomil; Pravastatin; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vasculitis | 2004 |
Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Cohort Studies; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2004 |
Telemonitoring of blood pressure self measurement in the OLMETEL study.
Topics: Adult; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Self Care; Telemedicine; Tetrazoles | 2004 |
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Monitoring, Physiologic; Olmesartan Medoxomil; Single-Blind Method; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2005 |
Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Imidazoles; Lisinopril; Male; Olmesartan Medoxomil; Renin; Renin-Angiotensin System; Tetrazoles | 2005 |
Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2006 |
Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2006 |
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2006 |
Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers.
Topics: Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glyburide; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2006 |
The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterioles; Biomarkers; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Vascular Resistance | 2006 |
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Time Factors; Treatment Outcome | 2006 |
Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Patient Compliance; Reproducibility of Results; Telemedicine; Tetrazoles; Time Factors; Treatment Outcome | 2006 |
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.
Topics: Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2007 |
[Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; China; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2006 |
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Losartan; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Single-Blind Method; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2007 |
Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diastole; Double-Blind Method; Drug Tolerance; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Nitrendipine; Olmesartan Medoxomil; Safety; Systole; Tetrazoles; Time Factors | 2007 |
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Diastole; Drug-Related Side Effects and Adverse Reactions; Female; Goals; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Systole; Tetrazoles; Treatment Outcome | 2007 |
Possible beneficial effect of olmesartan medoxomil on left atrial function in patients with hypertension : noninvasive assessment by acoustic quantification.
Topics: Acoustics; Angiotensin II Type 1 Receptor Blockers; Atrial Function, Left; Blood Pressure; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Outpatients; Patient Dropouts; Tetrazoles; Time Factors | 2008 |
Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil.
Topics: Adult; Age Factors; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Models, Biological; Olmesartan Medoxomil; Sex Characteristics; Tetrazoles | 2008 |
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2008 |
Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients.
Topics: Administration, Oral; Adult; Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diet, Sodium-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Radioimmunoassay; Renin; Safety; Tetrazoles; Treatment Outcome | 1997 |
Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Pulse; Renin; Renin-Angiotensin System; Respiration Disorders; Tetrazoles; Time Factors | 2001 |
89 other study(ies) available for olmesartan medoxomil and Blood Pressure, High
| Article | Year |
|---|---|
The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Clopidogrel; Computational Biology; Drug Therapy, Combination; Female; Humans; Hypertension; Ischemic Stroke; Male; Middle Aged; Olmesartan Medoxomil; Platelet Aggregation Inhibitors; Prognosis; Receptor, Angiotensin, Type 1; Treatment Outcome | 2021 |
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Female; Heart Disease Risk Factors; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Republic of Korea; Risk Factors; Tetrazoles | 2023 |
How to deal with the occurrence of rare drug-induced adverse events: the example of sprue-like enteropathy induced by olmesartan medoxomil and other angiotensin-receptor blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Celiac Disease; Humans; Hypertension; Incidence; Olmesartan Medoxomil; Patient Safety; Risk Assessment; Risk Factors | 2020 |
Olmesartan-associated duodenal villous atrophy, an emerging clinical issue.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrophy; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2020 |
Effectiveness of Olmesartan on Blood Pressure Control in Hypertensive Patients in India: A Real World, Retrospective, Observational Study from Electronic Medical Records.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Electronic Health Records; Humans; Hypertension; Imidazoles; India; Olmesartan Medoxomil; Retrospective Studies; Tetrazoles | 2020 |
[Effects of Olmesartan Medoxomil on Patients with Thoracic and Thoracoabdominal Aortic Aneurysm;Evaluation of Anti-hypertensive Effect and Possible Suppression of Aneurysmal Dilation( OLM 40 Study)].
Topics: Antihypertensive Agents; Aortic Aneurysm, Thoracic; Dilatation; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2020 |
Preparation of olmesartan medoxomil solid dispersion with sustained release performance by mechanochemical technology.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Oral; Biological Availability; Delayed-Action Preparations; Humans; Hypertension; Hypromellose Derivatives; Olmesartan Medoxomil; Particle Size; Solubility; Technology | 2022 |
Comments on: "Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension".
Topics: Blood Pressure; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2017 |
Long-term safety of different antihypertensive regimens: The risk of unfair comparisons.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Olmesartan Medoxomil; Oxadiazoles | 2018 |
Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
Topics: Administration, Oral; Animals; Diffusion; Drug Compounding; Drug Delivery Systems; Drug Liberation; Freeze Drying; Gastric Mucosa; Hypertension; Intestinal Mucosa; Lipids; Male; Nanoparticles; Olmesartan Medoxomil; Particle Size; Rats, Wistar; Static Electricity | 2018 |
Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.
Topics: Antihypertensive Agents; Benzimidazoles; Chlorthalidone; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Renal Insufficiency, Chronic; Tetrazoles | 2018 |
Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Female; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney; Male; Olmesartan Medoxomil; Ramipril; Tetrazoles | 2012 |
Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Chi-Square Distribution; Female; Glomerular Filtration Rate; Humans; Hypertension; Imidazoles; Kidney; Male; Multicenter Studies as Topic; Olmesartan Medoxomil; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Retrospective Studies; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome | 2012 |
Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Inbred Lew; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptors, G-Protein-Coupled; Renin; Renin-Angiotensin System; Tetrazoles | 2013 |
Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Chemokine CCL2; Dihydropyridines; Hypertension; Imidazoles; Inhibitor of Apoptosis Proteins; Kidney; Lipoproteins, LDL; Macrophages; Male; Nephrosclerosis; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Scavenger; Tetrazoles | 2013 |
Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Logistic Models; Losartan; Male; Middle Aged; Multivariate Analysis; Olmesartan Medoxomil; Retrospective Studies; Telmisartan; Tetrazoles; Treatment Outcome; Uric Acid; Valine; Valsartan | 2013 |
The influence of renin-angiotensin system genotypes on the antiproteinuric response to high doses of olmesartan in non-diabetic proteinuric nephropathies.
Topics: Adult; Alleles; Angiotensin Receptor Antagonists; Antihypertensive Agents; Disease Progression; Drug Therapy, Combination; Female; Genotype; Humans; Hypertension; Imidazoles; Male; Middle Aged; Mutagenesis, Insertional; Mutation, Missense; Olmesartan Medoxomil; Point Mutation; Polymorphism, Genetic; Proteinuria; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sequence Deletion; Tetrazoles | 2013 |
Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Apoptosis; Blotting, Western; Calcitonin Gene-Related Peptide; Cell Survival; Endothelium, Vascular; Female; Heme Oxygenase-1; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Stem Cells; Tetrazoles | 2014 |
Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
Topics: Absorption; Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Caco-2 Cells; Cell Membrane Permeability; Electric Conductivity; Emulsions; Humans; Hydrogen-Ion Concentration; Hypertension; Imidazoles; Male; Nanoparticles; Olmesartan Medoxomil; Particle Size; Rats; Rats, Wistar; Refractometry; Static Electricity; Tetrazoles; Thermodynamics; Viscosity | 2014 |
Angiotensin receptor blockers - advantages of the new sartans.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Telmisartan; Tetrazoles; Treatment Outcome | 2013 |
[Diarrhoea and malabsorption due to olmesartan use].
Topics: Antihypertensive Agents; Atrophy; Celiac Disease; Diagnosis, Differential; Diarrhea; Humans; Hypertension; Imidazoles; Male; Middle Aged; Netherlands; Olmesartan Medoxomil; Tetrazoles | 2014 |
A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Medication Adherence; Middle Aged; Odds Ratio; Olmesartan Medoxomil; Retrospective Studies; Tetrazoles | 2014 |
Olmesartan-induced enteropathy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Duodenal Diseases; Duodenoscopy; Duodenum; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2015 |
The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular System; Densitometry; Diastole; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Myosin-Light-Chain Phosphatase; Olmesartan Medoxomil; Phosphorylation; Receptor, Angiotensin, Type 1; Rho Guanine Nucleotide Exchange Factors; rho-Associated Kinases; rhoA GTP-Binding Protein; Systole | 2015 |
Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrogen; Cohort Studies; Creatinine; Dihydropyridines; Drug Combinations; Female; Glomerular Filtration Rate; Humans; Hypertension; Male; Middle Aged; Olmesartan Medoxomil; Potassium; Propensity Score; Retrospective Studies; Sodium; Tetrazoles; Uric Acid | 2016 |
Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension.
Topics: Absorption, Physiological; Adult; Age Factors; Aged; Antihypertensive Agents; Biological Variation, Population; Body Surface Area; Humans; Hypertension; Imidazoles; India; Metabolic Clearance Rate; Middle Aged; Models, Biological; Olmesartan Medoxomil; Prodrugs; Tetrazoles | 2017 |
Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor.
Topics: Allopurinol; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Enzyme Inhibitors; Hypertension; Imidazoles; Male; Myocardium; NG-Nitroarginine Methyl Ester; Olmesartan Medoxomil; Rats; Rats, Wistar; Tetrazoles; Time Factors; Uric Acid; Ventricular Remodeling; Xanthine Oxidase | 2008 |
Based treatment algorithm for essencial hypertension with olmesartan medoxomil.
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Reference Values; Severity of Illness Index; Tetrazoles; Treatment Outcome | 2008 |
Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Dizziness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Female; Headache; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Meta-Analysis as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles; Time Factors; Treatment Outcome | 2009 |
Early antihypertensive efficacy of olmesartan medoxomil.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cohort Studies; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles; Time Factors | 2008 |
Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Rate; Humans; Hypertension; Imidazoles; Japan; Male; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2009 |
Influence of guidelines on physicians' assessment of blood pressure lowering effects and achievement rate of blood pressure target during transitional period of guidelines.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Female; Guideline Adherence; Humans; Hypertension; Imidazoles; Japan; Male; Olmesartan Medoxomil; Physicians; Practice Guidelines as Topic; Prospective Studies; Risk Assessment; Tetrazoles; Treatment Outcome | 2009 |
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Edema; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tetrazoles | 2009 |
Estimating antihypertensive effects of combination therapy in an observational study using marginal structural models.
Topics: Antihypertensive Agents; Biometry; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Drug Therapy, Combination; Humans; Hypertension; Imidazoles; Logistic Models; Models, Statistical; Olmesartan Medoxomil; Probability; Prospective Studies; Randomized Controlled Trials as Topic; Tetrazoles | 2009 |
[Sevikar or Forzaten: olmesartan medoxomil and amlodipine besylate fixed combination in the treatment of hypertension].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2009 |
Efficacy of an olmesartan medoxomil-based treatment algorithm in patients stratified by age, race, or sex.
Topics: Age Factors; Aged; Antihypertensive Agents; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Racial Groups; Risk Assessment; Sex Factors; Tetrazoles; Treatment Outcome | 2010 |
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzimidazoles; Biological Transport; Biphenyl Compounds; Digoxin; Fluoresceins; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Membrane Transport Proteins; Mice; Multidrug Resistance-Associated Protein 2; Olmesartan Medoxomil; Tetrazoles; Thiophenes | 2010 |
Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
Topics: Adult; Antihypertensive Agents; Antioxidants; Blood Pressure; Blotting, Western; Clinical Trials as Topic; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Heme Oxygenase-1; Humans; Hypertension; Imidazoles; Italy; Leukocytes, Mononuclear; Lipoproteins, LDL; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NADPH Oxidases; Olmesartan Medoxomil; Oxidative Stress; Phosphorylation; Tetrazoles | 2011 |
Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Blood Glucose; Blood Pressure; CHO Cells; Cricetinae; Cricetulus; Dogs; Hypertension; Hypertension, Renal; Imidazoles; Insulin; Male; Olmesartan Medoxomil; Oxadiazoles; Protective Agents; Proteinuria; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Tetrazoles | 2011 |
Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Atenolol; Blood Pressure; Hemodynamics; Hypertension; Imidazoles; Kidney Diseases; Kidney Glomerulus; Male; Olmesartan Medoxomil; Peptide Fragments; Rats; Rats, Inbred SHR; Sclerosis; Tetrazoles | 2011 |
The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Infant; Models, Statistical; Olmesartan Medoxomil; Tetrazoles | 2012 |
Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blood Flow Velocity; Blood Pressure; Body Weight; Collagen; Disease Models, Animal; Hydroxyproline; Hypertension; Imidazoles; Male; NG-Nitroarginine Methyl Ester; Olmesartan Medoxomil; Pulsatile Flow; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Sulfonamides; Tetrazoles; Thiophenes; Vascular Stiffness | 2012 |
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain; Calcium Channel Blockers; Dihydropyridines; Disease Models, Animal; Drug Therapy, Combination; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Inbred SHR; Tetrazoles | 2012 |
[Hypertension: improved therapy adherence after switch to a fixed drug combinations].
Topics: Amlodipine; Antihypertensive Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Drug Substitution; Germany; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Medication Adherence; Olmesartan Medoxomil; Tetrazoles | 2012 |
Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA study.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Studies; Feeding Behavior; Female; Heart Rate; Humans; Hypertension; Imidazoles; Male; Metabolic Syndrome; Middle Aged; Olmesartan Medoxomil; Proportional Hazards Models; Prospective Studies; Tetrazoles | 2012 |
Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Hispanic or Latino; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2012 |
Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Asian People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; Hypertension; Imidazoles; Middle Aged; Olmesartan Medoxomil; Tetrazoles | 2012 |
Effects of angiotensin II AT₁-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in Dahl salt-sensitive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Diet, High-Fat; Endothelium, Vascular; Hydralazine; Hypertension; Imidazoles; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Superoxides; Tetrazoles; Thiobarbituric Acid Reactive Substances; Vasodilation | 2013 |
[Therapy of hypertension. AT1 blockers soon to be the first choice?].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2002 |
[Therapy of hypertension. A new rapidly effective AT1 blocker].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2002 |
Olmesartan (benicar) for hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Contraindications; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Survival Analysis; Tetrazoles | 2002 |
Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Atrial Natriuretic Factor; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Fibrosis; Gene Targeting; Guanylate Cyclase; Heart Rate; Heart Ventricles; Hypertension; Imidazoles; Mice; Mice, Knockout; Myocardium; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Organ Size; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Atrial Natriuretic Factor; RNA, Messenger; Tetrazoles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Ventricular Remodeling | 2002 |
Lower the pressure with a new antihypertensive.
Topics: Antihypertensive Agents; Contraindications; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2002 |
[New AT1-blocker is approved; "me too" or progress?].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cost Savings; Drug Approval; Germany; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2002 |
[Changed guidelines of the German High Blood Pressure League. AT(1) blocker in the first league now].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Losartan; Olmesartan Medoxomil; Tetrazoles; Time Factors | 2002 |
[New AT1 receptor antagonist. Rapid and effective blood pressure decrease].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Receptor, Angiotensin, Type 1; Tetrazoles | 2003 |
Chronic angiotensin II inhibition increases levels of calcitonin gene-related peptide mRNA of the dorsal root ganglia in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Calcitonin Gene-Related Peptide; Ganglia, Spinal; Gene Expression; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Thiazepines | 2003 |
Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cytokines; Hypertension; Imidazoles; Interferon-gamma; Interleukin-4; Kidney; Male; Nephritis, Interstitial; Olmesartan Medoxomil; Polymerase Chain Reaction; Proteinuria; Rats; Rats, Wistar; RNA, Messenger; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer; Tetrazoles | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Diuretics; Dizziness; Drug Combinations; Drug Interactions; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Olmesartan Medoxomil; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Rats; Tetrazoles; Time Factors; Valine; Valsartan | 2003 |
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat.
Topics: Angiotensin Receptor Antagonists; Animals; Animals, Congenic; Blood Pressure; Dinoprost; Disease Progression; Endothelin-1; Estradiol; F2-Isoprostanes; Female; Hypertension; Imidazoles; Male; Mice; Olmesartan Medoxomil; Ovariectomy; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin; Renin-Angiotensin System; Tetrazoles | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Germany; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Olmesartan Medoxomil; Placebos; Telmisartan; Tetrazoles; Therapeutic Equivalency; Thiophenes; Time Factors; Valine; Valsartan | 2003 |
[Not just blood pressure counts. How well are hypertensive patients controlled?].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2003 |
[Fast to the blood pressure goal. Lengthy dose adjustments harm compliance].
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Controlled Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Middle Aged; Olmesartan Medoxomil; Patient Compliance; Placebos; Sodium Chloride Symporter Inhibitors; Tetrazoles; Time Factors | 2003 |
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arteriosclerosis; Diabetes Mellitus; Disease Models, Animal; Humans; Hypertension; Imidazoles; Myocardial Infarction; Olmesartan Medoxomil; Rabbits; Ramipril; Rats; Tetrazoles; Time Factors | 2003 |
AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Diastole; Disease Progression; Drug Therapy, Combination; Extracellular Matrix; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Imidazoles; Inflammation; Male; Olmesartan Medoxomil; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thiazepines; Ventricular Dysfunction, Left | 2004 |
[From the beginning -- a strong-acting and well tolerable antihypertensive agent. The recipe against constant change].
Topics: Antihypertensive Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Olmesartan Medoxomil; Placebos; Tetrazoles; Time Factors | 2003 |
AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Hypertension; Imidazoles; Kidney; Kidney Tubules, Proximal; Male; Olmesartan Medoxomil; Proteinuria; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin; Tetrazoles | 2004 |
Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Bone Marrow Transplantation; Chemokine CCL2; Chemotaxis, Leukocyte; Enzyme Inhibitors; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Inflammation; Infusion Pumps, Implantable; Male; Mice; Mice, Inbred C57BL; Monocytes; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Olmesartan Medoxomil; Pilot Projects; Radiation Chimera; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptors, CCR2; Receptors, Chemokine; Recombinant Fusion Proteins; Superoxide Dismutase; Tetrazoles; Up-Regulation | 2004 |
Olmesartan improves endothelin-induced hypertension and oxidative stress in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Endothelin-1; Hydralazine; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Oxidative Stress; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Superoxides; Tetrazoles; Thiobarbituric Acid Reactive Substances | 2004 |
Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity.
Topics: Adipocytes; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Size; Epididymis; Fructose; Hypertension; Imidazoles; Insulin Resistance; Male; Muscle, Skeletal; Olmesartan Medoxomil; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Thiazepines; Triglycerides | 2004 |
[Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Heart Diseases; Humans; Hypertension; Imidazoles; Kidney Diseases; Olmesartan Medoxomil; Prodrugs; Tetrazoles; Vascular Diseases | 2004 |
[The drug of the month: Olmesartan medoxomil].
Topics: Antihypertensive Agents; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2004 |
Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cardiac Output, Low; Creatinine; Dihydropyridines; Drug Combinations; Echocardiography; Gene Expression; Hypertension; Imidazoles; Myocardium; Olmesartan Medoxomil; Organ Size; Rats; Rats, Inbred Dahl; Survival Analysis; Tetrazoles; Thiazepines | 2004 |
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Aorta, Thoracic; Atenolol; Carboxypeptidases; Carotid Arteries; Gene Expression Regulation, Enzymologic; Hydralazine; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles; Vasodilator Agents | 2005 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Disease Models, Animal; Dose-Response Relationship, Drug; Electroretinography; Glycated Hemoglobin; Heart Rate; Hypertension; Hypoxia; Imidazoles; Male; Olmesartan Medoxomil; Oxygen; Rats; Rats, Inbred SHR; Retinal Neovascularization; Tetrazoles | 2005 |
Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Dose-Response Relationship, Drug; Enalapril; Extracellular Matrix; Heart Rate; Hypertension; Imidazoles; Kidney; Male; Muscle, Smooth, Vascular; Myocytes, Cardiac; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles | 2005 |
[Olmesartan: antihypertensive therapy].
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypertension; Imidazoles; Multicenter Studies as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2005 |
Olmesartan medoxomil-induced angioedema.
Topics: Angioedema; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diltiazem; Face; Female; Humans; Hypertension; Imidazoles; Middle Aged; Neck; Olmesartan Medoxomil; Tetrazoles | 2007 |
[Effect of olmesartan medoxomil on arterial stiffness in patients with essential hypertension].
Topics: Antihypertensive Agents; Arteries; Female; Humans; Hypertension; Imidazoles; Male; Middle Aged; Olmesartan Medoxomil; Prospective Studies; Severity of Illness Index; Tetrazoles | 2007 |
The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hypertension; Imidazoles; Japan; Male; Olmesartan Medoxomil; Prospective Studies; Tetrazoles | 2008 |
The effects of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist on insulin resistance in fructose-fed rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Dietary Carbohydrates; Fasting; Fructose; Glucose; Glucose Clamp Technique; Heart Rate; Hypertension; Imidazoles; Insulin Resistance; Magnesium; Male; Muscle Fibers, Fast-Twitch; Muscle Fibers, Skeletal; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Olmesartan Medoxomil; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiazepines | 2000 |
The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Epididymis; Fructose; Glucose Clamp Technique; Heart Rate; Hypertension; Imidazoles; Insulin Resistance; Male; Muscle, Skeletal; Olmesartan Medoxomil; Rats; Rats, Sprague-Dawley; Tetrazoles; Thiazepines; Tumor Necrosis Factor-alpha | 2000 |
18th Scientific meeting of the International Society of Hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Chicago; Endothelin Receptor Antagonists; Enzyme Inhibitors; Humans; Hypertension; Imidazoles; Nitric Oxide Synthase; Olmesartan Medoxomil; Protease Inhibitors; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Societies, Medical; Tetrazoles | 2000 |
Pressure, platelets, and plaque: the central role of angiotensin II in cardiovascular pathology. Concluding comment.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cardiovascular Diseases; Fibrinolysis; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Renin-Angiotensin System; Tetrazoles | 2001 |
Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist.
Topics: Adult; Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cross-Over Studies; Diet, Sodium-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Hypertension; Imidazoles; Male; Multicenter Studies as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Severity of Illness Index; Tetrazoles | 2001 |
Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil.
Topics: Aged; Aging; Antihypertensive Agents; Female; Humans; Hypertension; Imidazoles; Kidney; Liver; Male; Middle Aged; Olmesartan Medoxomil; Reference Values; Tetrazoles | 2001 |
Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Captopril; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hypertension; Imidazoles; Losartan; Multicenter Studies as Topic; Olmesartan Medoxomil; Randomized Controlled Trials as Topic; Tetrazoles | 2001 |
[Effects of CS-866, an angiotensin II receptor antagonist, in 5/6 nephrectomized spontaneously hypertensive rats].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Hypertension; Imidazoles; Kidney Failure, Chronic; Male; Nephrectomy; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Tetrazoles; Thiazepines | 2001 |